It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress.
The abstracts ‘Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 179) and ‘Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 133) were presented at the virtual 62nd ASH Annual Meeting and Exposition, 5-8 December, 2020.
Questions
- Please could you give an overview of MEDI2228 and its mechanism of action? (0:07)
- What have the findings of the first-in human study taught us about the efficacy and safety of MEDI2228 in patients with relapsed/refractory multiple myeloma? (1:08)
- What is the rationale for the use of anti-BCMA CAR-T cells in the treatment of patients with relapsed/refractory multiple myeloma? (3:33)
- On the basis of data from Lummicar-2, how does CT053 CAR-T cell therapy compare with other CAR-T cell therapies in development for multiple myeloma? (4:46)
- What were your personal highlights of this year’s ASH virtual congress? (6:53)
Speaker Disclosures: Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio; Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca, and (with personal payment) Oncopeptides, Beigene and Antagene.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ASH 2020.
